Coherus Biosciences (CHRS) PT Lowered to $27 at Truist Securities
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $13.95 -1.06%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 42
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 42
Trade Now!
Join SI Premium – FREE
Truist Securities lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $27.00 (from $30.00) while maintaining a Buy rating.
You May Also Be Interested In
- FinecoBank (FBK:IM) PT Raised to EUR15.60 at Goldman Sachs
- Enerplus Corp. (ERF:CN) (ERF) PT Raised to Cdn$10 at TD Securities
- Enerplus Corp. (ERF:CN) (ERF) PT Raised to Cdn$7.50 at Scotiabank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
